Oyster Point Pharma, Inc. Common Stock
OYST
OYST was delisted on the 30th of December, 2022.
66 hedge funds and large institutions have $380M invested in Oyster Point Pharma, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 13 closing their positions.
5% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 20
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
8% less funds holding
Funds holding: 72 → 66 (-6)
27% less capital invested
Capital invested by funds: $520M → $380M (-$140M)
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$2.98M |
| 2 |
SCM
Sio Capital Management
New York
|
+$2.47M |
| 3 |
BlackRock
New York
|
+$1.59M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$1.53M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$1.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$12.1M |
| 2 |
MICM
Matthews International Capital Management
San Francisco,
California
|
-$6.5M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.38M |
| 4 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$1.89M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.72M |
OYST Hedge Fund Activity: Q3 2020 in Review
66 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Oyster Point Pharma, Inc. Common Stock (OYST) for Q3 2020, worth a combined $380M — down 27% from $520M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of OYST and 7 opened new positions — a net loss of 6 holders — while 20 trimmed existing stakes and 21 added.
The largest buyer was GW&K Investment Management, adding an estimated $2.98M. The largest seller was Wellington Management Group, cutting an estimated $12.1M.
- 66 institutional investors held Oyster Point Pharma, Inc. Common Stock (OYST) as of Q3 2020, down from 72 in Q2 2020.
- Funds reported $380M of Oyster Point Pharma, Inc. Common Stock stock for Q3 2020, down 27% quarter-over-quarter.
- 7 funds opened new Oyster Point Pharma, Inc. Common Stock positions in Q3 2020 and 13 closed out, a net change of -6 holders.
- The largest Oyster Point Pharma, Inc. Common Stock buyer in Q3 2020 was GW&K Investment Management, an estimated $2.98M added.
- The largest Oyster Point Pharma, Inc. Common Stock seller in Q3 2020 was Wellington Management Group, an estimated $12.1M sold.
Based on aggregated 13F filings for Q3 2020.